Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/34644
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3646]
Metadata
Show full item record
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY FOR CRITICALLY ILL HIV PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Author
Affilliation
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Unidade de Terapia Intensiva. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Unidade de Terapia Intensiva. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Unidade de Terapia Intensiva. Rio de Janeiro, RJ, Brasil.
Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Infectious Diseases Intensive. São Paulo, SP, Brazil.
Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Infectious Diseases Intensive. São Paulo, SP, Brazil.
Fundação Hospitalar do Estado de Minas Gerais. Hospital Eduardo de Menezes. Intensive Care Unit. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Unidade de Terapia Intensiva. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Unidade de Terapia Intensiva. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Unidade de Terapia Intensiva. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Unidade de Terapia Intensiva. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Unidade de Terapia Intensiva. Rio de Janeiro, RJ, Brasil.
Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Infectious Diseases Intensive. São Paulo, SP, Brazil.
Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas. Infectious Diseases Intensive. São Paulo, SP, Brazil.
Fundação Hospitalar do Estado de Minas Gerais. Hospital Eduardo de Menezes. Intensive Care Unit. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Unidade de Terapia Intensiva. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Unidade de Terapia Intensiva. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Unidade de Terapia Intensiva. Rio de Janeiro, RJ, Brasil.
Abstract
Introduction: It is unclear whether the treatment of an HIV infection with highly active antiretroviral therapy (HAART) affects intensive care unit (ICU) outcomes. In this paper, we report the results of a systematic review and meta-analysis performed to summarize the effects of HAART on the prognosis of critically ill HIV positive patients. Materials and methods: A bibliographic search was performed in 3 databases (PubMed, Web of Science and Scopus) to identify articles that investigated the use of HAART during ICU admissions for shortand long-term mortality or survival. Eligible articles were selected in a staged process and were independently assessed by two investigators. The methodological quality of the selected articles was evaluated using the Methodological Index for Non-Randomized Studies (MINORS) tool. Results: Twelve articles met the systematic review inclusion criteria and examined short-term mortality. Six of them also examined long-term mortality ( 90 days) after ICU discharge. The short-term mortality meta-analysis showed a significant beneficial effect of initiating or maintaining HAART during the ICU stay (random effects odds ratio 0.53, p = 0.02). The data analysis of long-term outcomes also suggested a reduced mortality when HAART was used, but the effect of HAART on long-term mortality of HIV positive critically ill patients remains uncertain. Conclusions: This meta-analysis suggests improved survival rates for HIV positive patients who were treated with HAART during their ICU admission.
Share